Transition Therapeutics plans $25 million at-the-market sale of stock

Cowen and Co. assists; proceeds used for general corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 6 – Transition Therapeutics Inc. has arranged a $25 million at-the-market sale of stock, according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Cowen and Co., LLC is the agent.

Proceeds will be used for general corporate purposes.

The biopharmaceutical company is based in Toronto.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.